Bank of America Forecasts Strong Price Appreciation for Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals (NASDAQ:AGIO) had its target price boosted by analysts at Bank of America from $32.00 to $34.00 in a report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s target price would suggest a potential upside of 17.65% from the stock’s current price.

AGIO has been the subject of several other reports. Wall Street Zen lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Leerink Partnrs raised Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, November 20th. Truist Financial set a $32.00 price target on shares of Agios Pharmaceuticals in a research note on Monday, November 24th. HC Wainwright dropped their target price on shares of Agios Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating for the company in a report on Thursday, November 20th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $38.22.

Agios Pharmaceuticals Stock Up 17.5%

Shares of NASDAQ AGIO opened at $28.90 on Wednesday. The stock has a market capitalization of $1.69 billion, a price-to-earnings ratio of -4.13 and a beta of 0.87. Agios Pharmaceuticals has a 52 week low of $22.24 and a 52 week high of $46.00. The firm has a 50-day simple moving average of $34.03 and a 200-day simple moving average of $36.26.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, topping the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative return on equity of 28.35% and a negative net margin of 895.86%.The business had revenue of $12.88 million for the quarter, compared to analysts’ expectations of $10.49 million. During the same period in the previous year, the firm posted $16.22 EPS. The business’s revenue for the quarter was up 43.3% compared to the same quarter last year. As a group, equities research analysts expect that Agios Pharmaceuticals will post -6.85 EPS for the current year.

Insider Buying and Selling

In other news, insider Sarah Gheuens sold 3,302 shares of the firm’s stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $43.92, for a total transaction of $145,023.84. Following the sale, the insider owned 61,727 shares of the company’s stock, valued at approximately $2,711,049.84. This trade represents a 5.08% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 3,902 shares of company stock valued at $170,754 over the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Agios Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. NewEdge Advisors LLC acquired a new stake in Agios Pharmaceuticals in the first quarter valued at $40,000. First Horizon Corp acquired a new position in Agios Pharmaceuticals during the third quarter worth about $45,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Agios Pharmaceuticals by 16.7% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 320 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Agios Pharmaceuticals during the 3rd quarter valued at approximately $79,000. Finally, Acadian Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals in the 1st quarter worth approximately $133,000.

More Agios Pharmaceuticals News

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: FDA approval: AQVESME (mitapivat) received FDA approval for anemia in adults with alpha‑ and beta‑thalassemia — making mitapivat the only approved oral therapy for these thalassemia types and opening a new commercial market for Agios. Business Insider: FDA Approves AQVESME
• Positive Sentiment: Regulatory detail & safety program: Approval includes a REMS/labeling requirement but confirms the indication expansion that investors had been anticipating, increasing near‑term revenue visibility. Zacks: Mitapivat Gets FDA Nod with REMS
• Positive Sentiment: Analyst upgrades/price target increases: Bank of America bumped its target to $34 (buy) and Truist raised its target to $38 and reiterated a buy — analysts cite the new indication as a revenue catalyst. Yahoo Finance: Price Target Raised
• Positive Sentiment: Commercial pricing and market expectation: Reports indicate list/pricing intentions near ~$425k per patient per year, which, combined with the exclusive oral label, supports material revenue potential if uptake and reimbursement follow. MSN: Pricing Report
• Neutral Sentiment: Media & transcript coverage: Multiple writeups, press releases and an investor/transcript slide deck circulated summarizing the approval and commercial plan — useful context for investors but incremental to the headline approval. Seeking Alpha: Approval Transcript
• Neutral Sentiment: Trading action: Shares were temporarily halted for a news release ahead of the announcement and volume spiked as the approval and analyst reactions hit the tape — heightened liquidity can amplify intraday moves.
• Negative Sentiment: Safety/label limitation: The approval includes a boxed warning/REMS for potential liver injury — this safety profile may temper prescribing, restrict use, and complicate commercial uptake. Seeking Alpha: Analysis and Risks
• Negative Sentiment: Revenue ceiling and payer risk: Several analysts/notes flag that thalassemia peak sales estimates (~$500M) may not be enough by itself to drive profitability; high list price could trigger payer restrictions or access delays. Seeking Alpha: Commercial Outlook
• Neutral Sentiment: Short interest note: Recent short‑interest data in the feed is anomalous/zero and likely not informative; monitor later filings for accurate short positioning.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.